# The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double‐blind, placebo‐controlled phase IIa trial of three dosage levels of CP‐690,550 versus placebo

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/the-safety-and-efficacy-of-a-jak-inhibitor-in-patients-with-active-rheumatoid/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Joel M. Kremer,Bradley J. Bloom,Ferdinand C. Breedveld,John Coombs,Mark P. Fletcher,David Gruben,Sriram Krishnaswami,Rubén Burgos‐Vargas,Bethanie Wilkinson,Cristiano A. F. Zerbini,Samuel H. Zwillich |
| Citations | 545 |
| DOI | 10.1002/art.24567 |
| Fields | Biochemistry, Genetics and Molecular Biology,Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W2101217991 |
| PMID | 19565475 |
| Type | article |
| Year | 2009 |

## Paper authors

- [David Gruben](https://scholariq.org/researchers/david-gruben/)

## Paper primary topic

- [Rheumatoid Arthritis Research and Therapies](https://scholariq.org/topics/rheumatoid-arthritis-research-and-therapies/)

## Paper topics

- [Rheumatoid Arthritis Research and Therapies](https://scholariq.org/topics/rheumatoid-arthritis-research-and-therapies/)
- [Cytokine Signaling Pathways and Interactions](https://scholariq.org/topics/cytokine-signaling-pathways-and-interactions/)
- [Melanoma and MAPK Pathways](https://scholariq.org/topics/melanoma-and-mapk-pathways/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.